Ocrelizumab accepted for EMA review
Ocrelizumab accepted for EMA review
Roche has announced that the European Medicines Agency (EMA) has validated the company’s Marketing Authorisation Application (MAA) of ocrelizumab for the treatment of relapsing multiple sclerosis (RMS) and primary progressive multiple sclerosis (PPMS) in the European Union (EU)...Read more - http://www.ms-uk.org/MSnews
MS-UK - http://www.ms-uk.org/
-
- Similar Topics
- Replies
- Views
- Last post
-
- 0 Replies
- 11022 Views
-
Last post by NHE
-
- 0 Replies
- 1031 Views
-
Last post by NHE
-
- 0 Replies
- 1825 Views
-
Last post by frodo
-
- 0 Replies
- 1165 Views
-
Last post by frodo
-
- 0 Replies
- 1965 Views
-
Last post by NHE
-
- 0 Replies
- 1638 Views
-
Last post by frodo
-
- 0 Replies
- 1170 Views
-
Last post by NHE
-
- 1 Replies
- 1606 Views
-
Last post by frodo
-
- 0 Replies
- 2219 Views
-
Last post by NHE